News

THR-18 is novel drug-candidate designed to reduce or neutralize the life-threatening adverse effects of tPA. The study has successfully defined the maximal tolerated and safe dose of THR-18

The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last

As part of the deal, Abide and Oxford will study the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain. The partnership will

The trial is designed to evaluate the efficacy and safety of gevokizumab in treating the active ulcers caused by this disease. In February 2014, the US Food and

Currently, participants are being sought for a new phase of a trial designed to measure the prevalence of addiction to OTC medicines. The University’s PhD student in Academic

Imbruvica is co-developed by Pharmacyclics and Janssen and commercialized outside the US by Janssen affiliates. Janssen affiliates market Imbruvica in Europe, Middle East and Africa as well as

As part of the deal, Waterstone has an option to license two additional cyclophilin inhibitors from Scynexis. In return, Scynexis will receive an upfront payment and is eligible

An active moiety of the prodrug isavuconazonium, Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed to treat severe invasive and life-threatening fungal infections. The

The drug is indicated for the long-term, once-daily, add-on maintenance treatment of asthma in patients 12 years of age and older who remain symptomatic on at least inhaled